The estimated Net Worth of Garry E Menzel is at least $8.73 Milhão dollars as of 10 July 2023. Garry Menzel owns over 47,702 units of TCR2 Therapeutics stock worth over $111,083 and over the last 12 years he sold TCRR stock worth over $133,786. In addition, he makes $8,482,210 as President, Chief Executive Officer, e Director at TCR2 Therapeutics.
Sign up
Garry Menzel TCRR stock SEC Form 4 insiders trading
Garry has made over 6 trades of the TCR2 Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 47,702 units of TCRR stock worth $43,409 on 10 July 2023.
The largest trade he's ever made was exercising 221,058 units of TCR2 Therapeutics stock on 1 December 2022 worth over $327,166. On average, Garry trades about 15,683 units every 21 days since 2012. As of 10 July 2023 he still owns at least 75,056 units of TCR2 Therapeutics stock.
You can see the complete history of Garry Menzel stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Garry Menzel biography
Dr. Garry E. Menzel is the President, Chief Executive Officer, Director of the Company. Dr. Menzel has also served on the board of directors and chairman of the audit committee of the oncology company Black Diamond Therapeutics Inc. since 2014. Previously, Dr. Menzel was the Chief Strategy Officer at Axcella Health Inc. from 2015 to 2016, the Chief Financial Officer at DaVita Healthcare Partners Inc. from 2013 to 2015, and the Chief Operating Officer at Regulus Therapeutics Inc. from 2008 to 2013. Dr. Menzel also had global leadership roles in running the biotechnology practices at Goldman Sachs & Co. LLC from 1994 to 2004 and Credit Suisse Group AG from 2004 to 2008. In addition, he was a consultant with Bain & Company and was a research assistant at SmithKline Beecham PLC (now GlaxoSmithKline PLC). Dr. Menzel received his Ph.D. from the University of Cambridge, where he studied the regulation of oncogenes in immune cells, and his M.B.A. from the Stanford University Graduate School of Business. Menzel is qualified to serve as a member of our board of directors because of his scientific background and corporate leadership experience.
What is the salary of Garry Menzel?
As the President, Chief Executive Officer, e Director of TCR2 Therapeutics, the total compensation of Garry Menzel at TCR2 Therapeutics is $8,482,210. There are no executives at TCR2 Therapeutics getting paid more.
How old is Garry Menzel?
Garry Menzel is 55, he's been the President, Chief Executive Officer, e Director of TCR2 Therapeutics since 2018. There are 6 older and 11 younger executives at TCR2 Therapeutics. The oldest executive at TCR2 Therapeutics Inc. is Neil Gibson, 63, who is the Independent Director.
What's Garry Menzel's mailing address?
Garry's mailing address filed with the SEC is C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVENUE, MILTON PARK, ABINGDON, X0, OX14 4RX.
Insiders trading at TCR2 Therapeutics
Over the last 6 years, insiders at TCR2 Therapeutics have traded over $15,820,150 worth of TCR2 Therapeutics stock and bought 4,788,512 units worth $65,684,711 . The most active insiders traders include Group, Llc Green Jeremy Red..., Kevin Ctang Capital Managem..., eAnsbert Gadicke. On average, TCR2 Therapeutics executives and independent directors trade stock every 36 days with the average trade being worth of $229,829. The most recent stock trade was executed by Kevin Ctang Capital Managem... on 25 May 2023, trading 50,000 units of TCRR stock currently worth $86,000.
What does TCR2 Therapeutics do?
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
What does TCR2 Therapeutics's logo look like?
Complete history of Garry Menzel stock trades at Adaptimmune Therapeutics Plc, Regulus Therapeutics Inc, DaVita Inc, Black Diamond Therapeutics Inc, TCR2 Therapeutics, eStoke Therapeutics
TCR2 Therapeutics executives and stock owners
TCR2 Therapeutics executives and other stock owners filed with the SEC include:
-
Garry Menzel,
President, Chief Executive Officer, Director -
Alfonso Cardama,
Chief Medical Officer -
Mayur Somaiya,
Chief Financial Officer -
Dr. Garry E. Menzel M.B.A., Ph.D.,
Pres, CEO & Director -
Dr. Alfonso Quintás Cardama M.D.,
Chief Medical Officer -
Mayur Amrat Somaiya,
Chief Financial Officer -
Dr. Patrick A. Baeuerle Ph.D.,
Founder & Member of the Advisory Board -
Carl Mauch,
IR Contact Officer -
Stephen Webster,
Independent Director -
Neil Gibson,
Independent Director -
Andrew Allen,
Independent Director -
Axel Hoos,
Director -
Patrick Baeuerle,
Director -
Robert Hofmeister,
Chief Scientific Officer -
Angela Justice,
Chief People Officer -
Ansbert Gadicke,
Independent Chairman of the Board -
Dr. Rosemary Harrison Ph.D.,
Chief Bus. & Strategy Officer -
Dr. Robert Hofmeister Ph.D.,
Chief Scientific Officer -
Stephen Turkowiak M.B.A.,
VP of Fin. & Treasurer -
Gregg McConnell M.B.A.,
Head of Bus. Devel. -
Dr. Angela Justice Ph.D.,
Chief People Officer -
Margaret Siegel J.D.,
VP & Head of Legal & Corp. Sec. -
Peter Olagunju,
Chief Technical Officer -
Eric Sullivan,
Chief Financial Officer -
Oncology Impact Fund L.P.On...,
-
Morana Globeways Holdings L...,
-
Morana Globeways Holdings I...,
-
Morana Globeways Holdings L...,
-
Morana Globeways Holdings L...,
-
Oncology Impact Fund L.P.On...,
-
Morana Globeways Holdings L...,
-
Investment Ltd China Molybd...,
-
Sun States Fund, L.P.Mpm As...,
-
Group, Llc Green Jeremy Red...,
-
Bio Ventures 2014, L.P.Fole...,
-
Shawn Tomasello,
Director -
Peter Olagunju,
Chief Operating Officer -
Priti Hegde,
Director -
Rosemary Harrison,
Chief Business & Strategy -
Kevin Ctang Capital Managem...,
-
Asset Management Llcevnin L...,